Tests an intensive team-based care program for people with type 1 diabetes
Tests a team, technology, education and peer support program in people with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
Key facts
- Where
- Beijing, Changsha, Chengdu, Hangzhou, Luoyang, Quanzhou, Shenyang, Shenzhen, Tangshan, and Wuhan, ChinaSee the 10 sites
Where in China
- Department of Endocrinology and Metabolism, Peking University People's HospitalBeijing, ChinaNot yet recruiting
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South UniversityChangsha, ChinaTaking people
- Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan UniversityChengdu, ChinaNot yet recruiting
- Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child HealthHangzhou, ChinaNot yet recruiting
- Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyang, ChinaTaking people
- Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical UniversityQuanzhou, ChinaNot yet recruiting
- Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical UniversityShenyang, ChinaNot yet recruiting
- Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen UniversityShenzhen, ChinaNot yet recruiting
- Second Department of Endocrinology and Metabolism, Tangshan Gongren HospitalTangshan, ChinaNot yet recruiting
- Department of Endocrinology, Zhongnan Hospital of Wuhan UniversityWuhan, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Xiangya Hospital of Central South University
- Trial code
- NCT07097818
- Record updated
- 3 September 2025
- Original description
The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.Read full original descriptionShow less
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2: a Multicentre, Cluster-randomized, Controlled Trial
The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.
Exclusion: Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening; Patients who have received red blood cell transfusions or erythropoiesis-stimulating agents within 3 months prior to screening; Patients who have used any oral, injectable, or intravenous corticosteroids within 8 weeks prior to screening, or who plan to use corticosteroids during the trial; Patients with alcohol or drug abuse; Patients who plan to undergo elective surgery requiring general anesthesia or dialysis during the study period; Patients who are currently participating in or have participated in other drug or device trials within the last 2 weeks; Patients who plan to receive diabetes treatment at other hospitals; Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies; Patients diagnosed with hematologic or bleeding disorders; Patients who, in the investigator's opinion, are not suitable for participation in this clinical trial, such as those with a history of vision impairment, eating disorders, celiac disease, etc; Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring; Patients with severe skin diseases that may affect the application sites of continuous glucose monitoring or insulin pump patches; Patients with auditory or visual impairments; Patients who plan to receive blood transfusions during the study period; Pregnant women, women planning to become pregnant within 1 year of the study, or women who are breastfeeding.
Eligibility criteria for study hospitals:; Members of the China Diabetes Type 1 Study (CD1S); Experience in type 1 diabetes management: treat more than 50 T1D patients per year and have held camp activities at least once; Have type 1 diabetes educators; Eligibility criteria of study participants:; Diagnosis of Type 1 Diabetes; Age ≥6 years, regardless of gender; Duration of disease >3 months; Planned to attend follow-up visits at this hospital within the next year; Possess sufficient cognitive ability to operate all study-related devices; Willing to use continuous glucose monitoring and insulin pumps, upload data, and participate in remote monitoring; Willing to attend structured education sessions and camp activities on time (for the intervention group only); Willing and able to adhere to the study protocol; Willing to sign the informed consent form.